反应详情

A round bottom flask was charged with tert-butyl 4-(2-(6-(N-(pyrimidin-4-yl)sulfamoyl)naphthalen-1-yl)-5-(trifluoromethyl)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate (Intermediate Y) (0.031 g, 0.051 mmol) and DCM (0.508 mL) and trifluoroacetic acid (3.91 μl, 0.051 mmol) was added. The resulting solution was maintained at rt for 18 h and then concentrated. The residue was taken up in minimal MeOH/DMSO and purified by preparative HPLC (Phenomenex C18 150×30 mm, 5 μm: 25 to 85% CH3CN:H2O (1% TFA modifier) over 15 min). Fractions were combined and concentrated to afford N-(pyrimidin-4-yl)-5-(2-(1,2,3,6-tetrahydropyridin-4-yl)-4-(trifluoromethyl)phenyl)naphthalene-2-sulfonamide 2,2,2-trifluoroacetate (8.8 mg, 0.014 mmol) as a colorless film. 1H NMR (400 MHz, CD3OD) δ ppm 1.98-2.28 (m, 2H) 2.73-2.97 (m, 2H) 3.41-3.62 (m, 2H) 5.70 (dt, J=3.15, 1.60 Hz, 1H) 7.16 (dd, J=6.36, 1.08 Hz, 1H) 7.52 (d, J=8.02 Hz, 1H) 7.60 (dd, J=7.04, 1.17 Hz, 1H) 7.64 (d, J=9.00 Hz, 1H) 7.68-7.82 (m, 3H) 7.94 (dd, J=8.90, 1.96 Hz, 1H) 8.17 (d, J=8.31 Hz, 1H) 8.30 (d, J=6.06 Hz, 1H) 8.59 (s, 1H) 8.71 (d, J=1.86 Hz, 1H); m/z (ESI, +ve ion) 510.9 (M+H)+.

1. additionwas added
2. concentrationconcentrated
3. custompurified by preparative HPLC (Phenomenex C18 150×30 mm, 5 μm: 25 to 85% CH3CN:H2O (1% TFA modifier) over 15 min)
4. concentrationconcentrated